Oxford Pharmascience adds Reckitt stalwart to board

Oxford Pharmascience added a big name in the OTC medicines industry to its board on Thursday, announcing the appointment of Anand Sharma as a non-executive director with immediate effect.

Pharmaceuticals & Biotechnology

19,328.21

16:34 19/11/24

0.64%

123.81

The AIM-traded medicine redevelopment firm said Sharma had worked in the pharmaceutical and consumer healthcare industry for more than 40 years, and was most recently the global category director for new business development at Reckitt Benckiser Healthcare, including the power brands Nurofen and Mucinex.

During his time at Reckitt, Sharma had a significant leadership role in the acquisition and integration of Boots Healthcare UK, Adams Respiratory USA and Paras Labs India.

He was a member of the Reckitt Benckiser Global Healthcare leadership team for more than 15 years, Oxford's board said, and had a deep understanding of the commercial aspects of the over-the-counter healthcare industry, including brand strategy, product innovation and geographical expansion strategy.

"I am delighted to welcome Anand to the board as he brings solid and impressive experience from within one of the best known OTC consumer healthcare companies," said non-executive chairman David Norwood.

"His knowledge of the sector and awareness of the issues facing OTC healthcare brands will be of great help to the Company as it looks to commercialise the OXPzero assets," he added.